Measuring retention in HIV care: the impact of data sources and definitions using routine data.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
01 04 2020
Historique:
pubmed: 1 2 2020
medline: 20 2 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

Measuring retention is critical for antiretroviral therapy (ART) management and program monitoring; however, many definitions and data sources, usually from single health facilities, are used. We used routine electronic data, linked across facilities, to examine the impact of definitions and data sources on retention estimates among women in Cape Town, South Africa. Retrospective cohort study. We compiled routine electronic laboratory, pharmacy and clinic visit data for 617 women who started ART during pregnancy (2013-2014) and estimated 24-month retention using different definitions and data sources. We used logistic regression to assess consistency of associations between risk factors and retention, and receiver operating characteristics analyses to describe how different retention estimates predict viremia at 12 months on ART. Using all available data sources, retention ranged from 41% (no gap >180 days) to 72% (100% 12-month visit constancy). Laboratory data (expected infrequently) underestimated retention compared with clinic visit data that identified more than 80% of women considered retained in all definitions. In all estimates, associations with known risk factors for nonretention remained consistent and retention declined over time: 77, 65 and 58% retained using all data sources in months 6-12, 12-18 and 18-24, respectively (P < 0.001). The 180-day gap definition was most strongly associated with viremia (odds ratio 24.3 95% confidence interval 12.0-48.9, all data sources). Researchers must carefully consider the most appropriate retention definition and data source depending on available data. Presenting more than one approach may be warranted to obtain estimates that are context-appropriate and comparable across settings.

Identifiants

pubmed: 32004202
doi: 10.1097/QAD.0000000000002478
pmc: PMC7109335
mid: NIHMS1557467
pii: 00002030-202004010-00011
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

749-759

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD074558
Pays : United States

Références

AIDS Care. 2016 Sep;28(9):1188-91
pubmed: 27010972
Matern Child Health J. 2015 Sep;19(9):2029-37
pubmed: 25656728
J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):508-516
pubmed: 27984555
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S156-S164
pubmed: 28498185
J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):574-80
pubmed: 23011397
J Int AIDS Soc. 2016 Apr 25;19(1):20679
pubmed: 27118443
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):427-438
pubmed: 29287029
Trop Med Int Health. 2018 Feb;23(2):136-148
pubmed: 29164754
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S111-S114
pubmed: 28498179
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
PLoS Med. 2011 Oct;8(10):e1001111
pubmed: 22039357
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):e106-8
pubmed: 23187944
BMC Genomics. 2008 Oct 16;9:488
pubmed: 18925949
Health Inf Manag. 2019 May;48(2):62-75
pubmed: 29898604
Trop Med Int Health. 2016 Aug;21(8):1003-1012
pubmed: 27208807
J Int AIDS Soc. 2016 Mar 21;19(1):20662
pubmed: 27005750
Curr HIV/AIDS Rep. 2015 Mar;12(1):1-5
pubmed: 25620530
J Clin Epidemiol. 2013 Sep;66(9):1006-13
pubmed: 23774112
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25114
pubmed: 30027583
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S123-S131
pubmed: 28498181
Trop Med Int Health. 2014 Nov;19(11):1360-6
pubmed: 25087778
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S190-S197
pubmed: 28498189
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):383-389
pubmed: 28225717
J Int AIDS Soc. 2014 Apr 28;17:18908
pubmed: 24780511
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e46-55
pubmed: 25692336
Am J Epidemiol. 2013 Sep 1;178(5):819-28
pubmed: 23785113
AIDS Patient Care STDS. 2010 Oct;24(10):607-13
pubmed: 20858055
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S173-S181
pubmed: 28498187
South Afr J HIV Med. 2017 Jul 27;18(1):694
pubmed: 29568630
J Acquir Immune Defic Syndr. 2014 Nov 1;67 Suppl 2:S150-6
pubmed: 25310122
PLoS Med. 2018 Mar 30;15(3):e1002547
pubmed: 29601570
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1287-90
pubmed: 26605986
Trop Med Int Health. 2017 Feb;22(2):161-170
pubmed: 27865052
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S207-S215
pubmed: 28498191
AIDS Res Treat. 2017;2017:3527563
pubmed: 28469942
BMC Public Health. 2014 Oct 04;14:1035
pubmed: 25280535
AIDS. 2014 Feb 20;28(4):599-601
pubmed: 24469000
Glob Health Action. 2018;11(1):1440782
pubmed: 29502484
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):e125-32
pubmed: 23807157
BMJ Glob Health. 2018 Apr 24;3(Suppl 2):e000565
pubmed: 29713507
AIDS Care. 2018 Mar;30(3):267-277
pubmed: 28942713
Lancet HIV. 2016 Apr;3(4):e175-82
pubmed: 27036993
J Acquir Immune Defic Syndr. 2010 Mar;53(3):405-11
pubmed: 19745753
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S140-S148
pubmed: 28498183
BMC Public Health. 2018 Mar 20;18(1):374
pubmed: 29558896
J Int AIDS Soc. 2016 Jul 20;19(5 Suppl 4):20837
pubmed: 27443268
AIDS Patient Care STDS. 2017 Aug;31(8):335-341
pubmed: 28650703
Clin Infect Dis. 2016 Apr 1;62(7):935-944
pubmed: 26679625
J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):77-83
pubmed: 24963086
J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S189-96
pubmed: 27355508
J Int AIDS Soc. 2014 Jul 28;17:18994
pubmed: 25079437
PLoS Med. 2018 Jun 11;15(6):e1002589
pubmed: 29889844

Auteurs

Tamsin K Phillips (TK)

Division of Epidemiology & Biostatistics.
Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town.

Catherine Orrell (C)

Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine.
Department of Medicine, University of Cape Town, Cape Town, South Africa.

Kirsty Brittain (K)

Division of Epidemiology & Biostatistics.
Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town.

Allison Zerbe (A)

ICAP at Columbia University, Mailman School of Public Health.

Elaine J Abrams (EJ)

ICAP at Columbia University, Mailman School of Public Health.
Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.

Landon Myer (L)

Division of Epidemiology & Biostatistics.
Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH